Connection

Ki Chung to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Ki Chung has written about Dose-Response Relationship, Drug.
Ki Chung
Connection Strength
0.035
Dose-Response Relationship, Drug
  1. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 10 01; 27(19):5236-5247.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.